{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-23-000020","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.913723+00:00","generated_at":"2026-06-12T08:43:30.618099+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera Q2 revenue drops 78% to $10M; net loss widens to $0.11/share","bullets":["Total revenue $10.1M vs $45.9M in Q2 2022; research fees fell to $9.8M from $12.5M.","Net loss $30.5M ($0.11/sh) vs net loss $6.8M ($0.02/sh) in Q2 2022; R&D spending rose to $36.5M.","Cash, equivalents and marketable securities $822.9M; secured $220M in strategic financing from Canadian govts.","Cumulative partnered program starts up 20% YoY to 106; 9 molecules advanced to clinic vs 6 a year ago.","Total programs under contract 177 with 41 partners, up from 164 and 38 a year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-23-000020","json":"https://secwatch.observer/filing/0001703057-23-000020.json","markdown":"https://secwatch.observer/filing/0001703057-23-000020.md","text":"https://secwatch.observer/filing/0001703057-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/abcl-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:43:30.618099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12babcba7544ed7a978e3c5edbcfd0eccfe44484","claim":"AbCellera Biologics Inc. reported the second quarter of 2023 results: revenue $10.1 million, net income $30.5 million, EPS $(0.11) per share on a basic and diluted basis.","evidence_excerpt":"this funding will drive value in multiple dimensions of our business, including advancing more pre-partnered programs to the clinic.” Q2 2023 Business Summary ● Earned $10.1 million in total revenue. ● Generated a net loss of $30.5 million, compared to a net loss of $6.8 million in Q2 2022. ● Maintained a cumulative total of 177 programs under contract with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$10.1 million"},{"label":"Net income","value":"$30.5 million"},{"label":"EPS","value":"$(0.11) per share on a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"93362d06fb08a6634d679536e13a9af8d419efb1","claim":"AbCellera Biologics Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}